Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs

@article{Armanini2014AldosteroneRB,
  title={Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs},
  author={D. Armanini and C. Sabbadin and G. Dona' and G. Clari and L. Bordin},
  journal={Expert Opinion on Pharmacotherapy},
  year={2014},
  volume={15},
  pages={909 - 912}
}
Canrenone is a derivative of spironolactone with lower antiandrogen activity. The drug is used only in few countries and can block all the side effects of aldosterone (ALDO). The drug is effective even in the presence of normal concentrations of ALDO. Mineralcorticoid receptor antagonists block the inflammatory activity of ALDO at the level of target tissues as heart, vessels and mononuclear leukocytes. Canrenone reduces the progression of insulin resistance and of microalbuminuria in type 2… Expand
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
TLDR
The novelty of this observation relies on the independent positive impact of canrenone on the all-cause mortality and clinical improvement of COVID-19 patients ranging from moderate to severe diseases. Expand
The story of spironolactones from 1957 to now: from sodium balance to inflammation.
TLDR
Considering all the benefits of MR-antagonists, their use should be reconsidered not only for the treatment but also for the prevention of many clinical situations. Expand
Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment
TLDR
Treatment with canrenone at doses that effectively controlled hypokalemia and blood pressure values did not preclude the diagnosis in PA patients, while the addition of the angiotensin type 1 receptor blocker olmesartan raised the false negative rate, reducing the ARR. Expand
Mineralocorticoid receptor antagonist effect on aldosterone to renin ratio in patients with primary aldosteronism.
TLDR
It is demonstrated that canrenone exerted a deep impact on the diagnostic accuracy of the screening test for primary aldosteronism: the rate of false negative tests raised to 16.7% after 2 weeks, 8 weeks, 2-6 months and 7-12 months of mineralocorticoid receptor antagonist treatment, respectively. Expand
Interfering with mineralocorticoid receptor activation: the past, present, and future
TLDR
Advances have been made that could potentially increase the clinical use of agents that inhibit the actions of aldosterone, and these will be discussed here along with some examples of the beneficial effects of these new therapeutic agents. Expand
Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology
TLDR
Excess mineralocorticoid signaling now appears deleterious in the progression of pathologies that may lead to end-stage organ failure and could therefore benefit from the repositioning of pharmacological MR antagonists. Expand
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial
TLDR
Adding treatment with high-dose spironolactone to usual care for patients with AHF for 96 hours was well tolerated but did not improve the primary or secondary efficacy end points. Expand
A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis
TLDR
Data from the most extensively studied population, individuals with diabetes, do not support a long-term glycemic impact in these patients and further prospective studies are necessary to establish spironolactone's true biological effects and their clinical implications. Expand
Novel RAAS agonists and antagonists: clinical applications and controversies
TLDR
The present and future pharmacological manipulation of this important system is summarized and other potential therapeutic targets emerge, which could provide improved cardiovascular and renal protection beyond that provided by an ACE inhibitor or ARB. Expand
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients
TLDR
Canrenone and HCTZ have a similar effect on BP; however, canrenone seems to improve metabolic parameters, while H CTZ worsens them. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 17 REFERENCES
The spironolactone renaissance
TLDR
Clinical trials have shown that spironolactone reduces cardiac and vascular collagen turnover, improves heart variability, reduces ventricular arrhythmias, improves endothelial dysfunction and dilates blood vessels in human heart failure and these effects probably all contribute to the increased survival in heart failure. Expand
Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
TLDR
Mineralocorticoid receptor antagonism prevents the effect of activation of the renin-angiotensin-aldosterone system on PAI-1 antigen in normotensive subjects and improves fibrinolytic balance in hypertensive subjects through a potassium-independent mechanism. Expand
Effect of canrenone and amiloride on the prooxidative effect induced by aldosterone in human mononuclear leukocytes in vitro.
TLDR
Comparing the effect of potassium-sparing diuretics amiloride and canrenone on the protein expression of p22phox, a NADPH-oxidase system subunit, that is a principal marker of production of superoxide anions, confirms the prooxidative effect of aldosterone in MNL. Expand
Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
TLDR
This study questions the traditional view that the mode of action of spironolactone is via its metabolite canrenone, and suggests that the two antialdosterone drugs appear to act through partially different metabolites. Expand
Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria
TLDR
Findings indicate that, despite similar BP-lowering effect, the addition of canrenone to valsartan/amlodipine combination was more effective in reducing UAE than HCTZ addition. Expand
Treatment of polycystic ovary syndrome with spironolactone plus licorice.
TLDR
In patients with PCOS the mineralocorticoid properties of licorice can reduce the prevalence of side effects related to the diuretic activity of spironolactone. Expand
Effects of canrenone in patients with metabolic syndrome
TLDR
Canrenone seems to be effective in reducing some factors involved in metabolic syndrome and in improving insulin-resistance and the inflammatory state observed in patients affected by metabolic syndrome. Expand
IN‐VIVO METABOLITES OF SPIRONOLACTONE AND POTASSIUM CANRENOATE: DETERMINATION OF POTENTIAL ANTI‐ANDROGENIC ACTIVITY BY A MOUSE KIDNEY CYTOSOL RECEPTOR ASSAY
TLDR
Since over 80% of administered spironolactone is irreversibly converted to canrenone/canrenoic acid, its much higher anti‐androgen activity on radioreceptor assay and bioassay may point to the generation of unidentified, minor metabolites with very high affinity for androgen receptors and/or a very long plasma half‐life. Expand
Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies
  • B. Pitt
  • Medicine
  • Molecular and Cellular Endocrinology
  • 2004
TLDR
Increasing evidence suggest that aldosterone blockade has important effects not only on the kidney but on ventricular remodeling, myocardial fibrosis, autonomic balance, fibrinolysis, oxidative stress, and activation of the NF-kappaB and AP-1 signaling pathways. Expand
Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study.
TLDR
Treatment with canrenone given on the top of optimal therapy in patients with MetS and chronic, stabilized HF with reduced EF, protects deterioration of MME, improves diastolic dysfunction and maximizes the decrease in BNP. Expand
...
1
2
...